The advisory support will consist of a comprehensive feasibility study with functional planning and preliminary designs for the hospital.
The new hospital will be a zero-emission building linked with the existing Burgas University hospital.
The European Investment Bank (EIB), funded by the European Investment Advisory Hub (EIAH), will provide support to the Municipality of Burgas, Bulgaria, to facilitate project preparation for the construction of the first children’s hospital in the country.
The construction of the new hospital is an integral part of the Burgas Municipality’s Investment Programme for the period 2020-2023 and is also considered as an important component of the country’s healthcare strategy by the Ministry of Health. The new hospital will address the healthcare needs of children and adolescents in the city of Burgas, one of the fastest growing cities in Bulgaria.
EIB Vice-President Lilyana Pavlova, who oversees EIB Advisory Services, said: “Advisory support from the EU bank will be key to unlocking investments in the healthcare sector in Bulgaria. This support also comes at a crucial time, in the aftermath of the COVID-19 crisis, and I am very glad we will be able to support one of Bulgaria’s largest cities in delivering state-of-the-art healthcare infrastructure to its people.The EIAH support is a good example of how the EIB can bring together internal and local consultancy expertise to tackle a long-term challenge within a Member State and help bring forward an investable project.”
European Commissioner for the Economy, Paolo Gentiloni, said: “The European Investment Advisory Hub is a fundamental component of the Investment Plan for Europe. Financing a project is the main objective, and sometimes to help unlock that financing, project promoters need technical assistance to get their plans ready. With support provided by the Advisory Hub, soon the Municipality of Burgas will boast the first children’s hospital in Bulgaria, which is something to celebrate.”
Mayor of Burgas Dimitar Nikolov, stated: “A major goal of the administration of the City of Burgas is to constantly improve the quality of life of our citizens. The current partnership between the Municipality of Burgas and the EIB is yet another opportunity for us to do so, as it will allow us to invest in a sector of great importance for our city – child healthcare. Building a new hospital that specialises in providing medical care to children is not only important for Burgas, but for the south-eastern region of Bulgaria as a whole. It will enable medical professionals to provide efficient treatment to child patients with serious medical conditions and will eliminate the unnecessary risks involved in transporting them to major hospitals in Sofia. Moreover, the newly established medical institutions will be closely linked with the Medical Faculty of our University, which is another significant step forward in the accomplishment of our long-standing goal to make Burgas a centre of outstanding medical education. With its support, the EIB has once again proven to be a powerful ally, determined to endorse the progress of our society. We are now safe in the knowledge that the future of our community is bright, as we are ‘standing on the shoulders of giants’!”
The advisory support from the EIB and international consultancy experts will provide the municipality with a comprehensive feasibility study that will include functional planning and preliminary designs for the hospital, in line with best international practices and standards. The advisory support will also be key to unlocking access to finance for this ambitious project, including potentially from the European Structural and Investment Funds and the EIB (under the European Fund for Strategic Investments).
The new facility will be of particular importance for the region due to its concentration of established healthcare facilities and educational programmes. The project, due to be completed by 2024, will also support economic growth and facilitate specialist employment, attracting more investment to a key sector of the Bulgarian economy.
The European Investment Advisory Hub (EIAH) is a partnership between the European Investment Bank Group and the European Commission under the Investment Plan for Europe. The EIAH is designed to act as a single access point to various types of advisory and technical assistance services. It supports the identification, preparation and development of investment projects across the EU. Its advisers work directly with project promoters to prepare a tailor-made advisory package to support investment projects.
The EIB and the Instituição Financeira de Desenvolvimento (IFD) have joined forces to finance a €400 million investment programme aimed at upgrading infrastructure for long-term and elderly care across Portugal, involving approximately 150 projects. The funds will be channelled to third-sector entities already providing services for the elderly in Portugal, in particular in the fields of health, accommodation and social support.
The EIB and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the signing of a €24.5 million financing agreement. The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19). In addition, it is also intended to support the potential expansion of the CALVID-1 trial into a confirmatory phase 3 trial and the commercial-scale manufacturing for IMU-838. Immunic AG, the German subsidiary of Immunic, Inc., will receive the EIB loan in three tranches upon the completion of pre-defined milestones.
The EIB and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. Atriva’s ATR-002, an oral small molecule, has been proven to block the viral propagation of SARS-CoV-2 in pre-clinical trials, making it a much-needed therapeutic option for patients with moderate to severe COVID-19 symptoms who require hospitalisation.